Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
CLSPN small interfering RNA treatment decreased GC cell proliferation and invasion.
|
30240769 |
2019 |
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CLSPN small interfering RNA treatment decreased GC cell proliferation and invasion.
|
30240769 |
2019 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
CLSPN small interfering RNA treatment decreased GC cell proliferation and invasion.
|
30240769 |
2019 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among these dysregulated RNAs, three DELs (AP002478.1, HTR2A-AS1, and ERVMER61-1) and six DEGs (enhancer of zeste homolog 2 [<i>EZH2</i>], kinesin family member 23 [<i>KIF23</i>], chromobox 2 [<i>CBX2</i>], centrosomal protein 55 [<i>CEP55</i>], cell division cycle 25A [<i>CDC25A</i>], and claspin [<i>CLSPN</i>]) were used for construct a prognostic signature for HCC overall survival (OS), and performed well in HCC OS (adjusted <i>P</i><0.0001, adjusted hazard ratio = 2.761, 95% confidence interval = 1.838-4.147).
|
31289599 |
2019 |
Ovarian clear cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The HNF-1β-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma.
|
29707125 |
2018 |
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Functional analyses indicated that the expression TopBP1 and Claspin positively affects the survival of cancer cells and thus negatively the xenograft metastasis model animals in response to radiation.
|
25216549 |
2014 |
Metastatic malignant neoplasm to brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases.
|
25216549 |
2014 |
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6).
|
25216549 |
2014 |
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6).
|
25216549 |
2014 |
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6).
|
25216549 |
2014 |
Ataxia Telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both the ATR (ataxia telangiectasia and Rad3-related protein) kinase and the Replication pausing complex (RPC) components Tipin, Tim1 and Claspin play key roles in activating the intra S-phase checkpoint and in stabilizing the stalled replication forks.
|
22324461 |
2012 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results evidenced a constant and significant increase of the rate of claspin positivity from the normal tissues to carcinomas (pχ2(trend) < 0.0001).
|
22731782 |
2012 |
Solid Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Claspin expression is significantly high in several human solid tumors.
|
22731782 |
2012 |
Human papilloma virus infection
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas).
|
22731782 |
2012 |
Breast Cancer, Familial
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is the first study reporting the mutation screening of the CLSPN gene in familial breast cancer cases.
|
18077083 |
2008 |
Mammary Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A separate analysis of the CLSPN c.3839C>T (rs35490896) variant that was observed more frequently in breast tumors than in pancreatic tumors or normal controls failed to detect a significant association with breast cancer risk in a Mayo Clinic breast cancer case-control study.
|
18281469 |
2008 |
Mammary Neoplasms
|
0.020 |
Biomarker
|
group |
LHGDN |
Germline alterations in the CLSPN gene in breast cancer families.
|
18077083 |
2008 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor.
|
28942358 |
2017 |
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor.
|
28942358 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas).
|
22731782 |
2012 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas).
|
22731782 |
2012 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We resequenced CLSPN from the germline of selected cancer families with a history of breast cancer (n = 25) or a multicancer phenotype (n = 46) as well as from a panel of sporadic cancer cell lines (n = 52) derived from a variety of tumor types.
|
19737971 |
2009 |
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we describe a study to determine whether mutational disruption of CLSPN contributes to cancer susceptibility and sporadic tumorigenesis.
|
19737971 |
2009 |
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Subsequent studies showed that BME treatment of breast cancer cells inhibited survivin and claspin expression.
|
20179194 |
2010 |
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We resequenced CLSPN from the germline of selected cancer families with a history of breast cancer (n = 25) or a multicancer phenotype (n = 46) as well as from a panel of sporadic cancer cell lines (n = 52) derived from a variety of tumor types.
|
19737971 |
2009 |